UroGen Pharma Stock Falls 5% After Signing Deals With IntraGel Therapeutics
(RTTNews) - Shares of UroGen Pharma Ltd. (URGN) are falling about 5 percent in Thursday morning trading after the company entered into an equity investment agreement and a strategic Option and Research License Agreement with IntraGel Therapeutics.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.